Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England &...
Cancer
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer...
Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development
CALGARY, Alberta, June 02, 2023 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA)...
Celldex Therapeutics to Present at Jefferies Healthcare Conference
HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a...
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of...
Folia Health joins the Cancer Moonshot’s CancerX Public-Private Partnership as a Founding Member
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Folia Health, a health technology company and a leader in patient-centered outcomes research,...
Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision...
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on...
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
Sydney, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited, an Australian company (ASX: IMM) (Nasdaq: IMMP) (Immutep or the...
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with...
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in...
OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer
Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a...
Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy
Brings total Series A funding to over $28 million allowing CyPep-1 to advance into Phase 2 Bergen, Norway, June 2,...
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and...
The International Myeloma Foundation (IMF) Honors 2023 Research Achievement Awardees, Dr. Maria-Victoria Mateos and Dr. Thomas Martin
LOS ANGELES, June 01, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce the recipients of...
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company – – YUSIMRY will...
Culture Biosciences Establishes Advisory Board of Biotech and Biopharma Executives to Guide the Corporate Strategy and Accelerate Growth
Seasoned sector leaders will advise Culture’s leadership in customer intelligence and innovationSAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Culture...
Ambrx to Present at Multiple Upcoming Investor Meetings
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced...
Palette Life Sciences Welcomes New Barrigel® Center of Excellence Program Designations
Recognizing exceptional leadership in patient education and clinical skill in the Barrigel procedure SANTA BARBARA, Calif. and STOCKHOLM, Sweden, May...
Aprea Therapeutics to Present at BIO International Convention
DOYLESTOWN, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused...